Clinical Practice

Scabies

Olivier Chosidow, M.D., Ph.D.

N Engl J Med 2006; 354:1718-1727April 20, 2006

Article

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

A 30-year-old man notes diffuse, intense itching. He reports that his girlfriend has the same itching. Examination of the skin reveals interdigital lesions, with small papules, vesicles, and excoriations on the hands, and indurated nodules on the genitalia, all suggestive of classic scabies. How should this case be managed?

The Clinical Problem

Nature of the Infection

Scabies is a common parasitic infection caused by the mite Sarcoptes scabiei variety hominis, an arthropod of the order Acarina. The worldwide prevalence has been estimated at about 300 million cases yearly, although this may be an overestimate. Scabies occurs in both sexes, at all ages, in all ethnic groups, and at all socioeconomic levels. In an epidemiologic study in the United Kingdom, scabies was shown to be more prevalent in urban areas and among women and children and more common in winter than in summer.1 Scabies is generally a nuisance on account of itching, rash, and its ability to spread among people; superinfection may also occur. The risk of severe outbreaks and complicated scabies is particularly high in institutions (including nursing homes and hospitals) and among socially disadvantaged populations and immunocompromised hosts.

The mite is an obligate parasite that completes its entire life cycle on humans. Only female mites burrow into the skin (Figure 1Figure 1Adult Gravid Scabies Mite.). The maturation process lasts about 15 days, with the larvae emerging 2 to 3 days after the eggs are laid.2 About 5 to 15 female mites live on a host infected with classic scabies, but the number can reach hundreds or even millions in cases of crusted scabies. The skin eruption of classic scabies is considered a consequence of both infestation and a hypersensitivity reaction to the mite. The incubation period before symptoms occur is three to six weeks for primary infestation but may be as short as one to three days in cases of reinfestation.

Transmission

Mites cannot fly or jump but crawl at the rate of 2.5 cm per minute on warm skin. They can survive for 24 to 36 hours at room temperature and average humidity and remain capable of infestation and epidermal burrowing.3 The more parasites on a person, the greater the likelihood of transmission, either direct (i.e., skin-to-skin contact) or indirect (e.g., through infested bedding, clothing, or other fomites).

The predominant route of transmission is direct skin-to-skin contact. Transmission by means of shared clothing or other indirect method is rare with classic scabies but may occur with crusted scabies (e.g., in immunocompromised hosts). Transmission among family members and in institutional settings is common.

Sexual transmission also occurs. In a study of risk factors for scabies in a clinic for sexually transmitted infections,4 high-risk persons included men who have sex with men and men with sporadic sexual contact. There is no evidence to suggest that mites can transmit infection with the human immunodeficiency virus (HIV).

Strategies and Evidence

Diagnosis

The diagnosis of scabies rests largely on the history and examination of the patient, as well as on the history of the family and close contacts. Classic manifestations of scabies include generalized and intense itching, usually sparing the face and head. Pruritus is worse at night. The lesions are located mostly in the finger webs (Figure 2AFigure 2Classic Scabies.), on the flexor surfaces of the wrists, on the elbows, in the axillae, on the buttocks and genitalia (Figure 2B), and on the breasts of women (Figure 2C). Inflammatory pruritic papules are present at most sites. Burrows (Figure 2D) and nodules (generally in the genital regions and axillae) are specific for scabies but may be absent. Nonspecific secondary lesions, including excoriations, eczematization (Figure 2E), and impetiginization, may occur anywhere.

In a report from a sub-Saharan region where there is a high (13 percent) prevalence of scabies, the presence of diffuse itching and visible lesions associated with either at least two typical locations of scabies or a household member with itching had 100 percent sensitivity and 97 percent specificity for the diagnosis.5 Such data are lacking from areas with a lower prevalence of scabies.

Scabies occasionally presents in atypical forms6 (Table 1Table 1Special Forms of Scabies.) that are more difficult to diagnose than the classic forms and, therefore, may be more likely to lead to outbreaks. Atypical presentations in infants often involve the face, scalp, palms, and soles. Atypical papular scabies occurs in the elderly, localized or generalized crusted scabies in immunocompromised patients, and impetigo in patients whose scabies is superinfected (Figure 3A through 3FFigure 3Special Forms of Scabies.).

Diagnostic Tests

Definitive diagnosis relies on the identification of mites, eggs, eggshell fragments, or mite pellets. Multiple superficial skin samples should be obtained from characteristic lesions — specifically, burrows or papules and vesicles in the site of burrows — by scraping laterally across the skin with a blade, taking care to avoid bleeding. The specimens can be examined with a light microscope under low power (Figure 1). Potassium hydroxide should not be used, because it can dissolve mite pellets. Since the number of mites is low in cases of classic scabies, this technique is highly operator dependent. Failure to find mites is common and does not rule out scabies.

In atypical cases or when direct examination is not possible, a skin biopsy may potentially confirm the diagnosis (Figure 4Figure 4Adult Sarcoptes scabiei in Its Burrow (Arrow) at the Upper Part of an Acanthotic Epidermis (Hematoxylin and Eosin).). However, mites or other diagnostic findings are frequently absent, and the histologic examination usually shows a nonspecific, delayed hypersensitivity reaction.7 Despite the relatively low sensitivity of diagnostic testing, empirical treatment is not recommended for patients with generalized itching and should be reserved for patients with a history of exposure, a typical eruption, or both.

Treatment

Infested persons and their close physical contacts should be treated at the same time, regardless of whether symptoms are present. Topical or oral products may be used, although there are few rigorous studies to guide their use. Table 2Table 2Current Treatments for Scabies. summarizes doses and side effects of agents commonly used to treat scabies.

Topical

Permethrin and lindane are the two most studied topical treatments for scabies. A Cochrane meta-analysis of four randomized trials comparing these agents indicated that permethrin (given as a single overnight application) was more effective than lindane (odds ratio for clinical failure, 0.66; 95 percent confidence interval, 0.46 to 0.95).8,9 However, there was considerable heterogeneity in effects among studies in the meta-analysis. In the largest trial, there was no difference in clinical cure rates; at an average of 28 days after treatment, complete resolution had occurred in 181 of 199 patients treated with permethrin (91 percent) and in 176 of 205 patients given lindane (86 percent).10

Nevertheless, the potential neurotoxicity of lindane, especially with repeated applications, has limited its use11; the product is no longer available in the United Kingdom or Australia. In an in vitro model assessing systemic exposure during conditions of overuse, the risk of adverse effects with the use of 5 percent permethrin cream was estimated to be lower by a factor of at least 40 than the risk associated with the use of 1 percent lindane lotion.12 In patients, the rate of central nervous system side effects reported by physicians to be at least possibly related to permethrin was low in a 1996 report (1 per 500,000 U of distributed permethrin), with no serious events.13 Despite its higher cost than lindane, 5 percent permethrin is recommended by the Centers for Disease Control and Prevention (CDC) as first-line topical therapy for scabies.14 Mass treatment with permethrin has also been effective in controlling scabies in communities in which it is endemic.

Other topical treatments include benzyl benzoate (not available in the United States) and crotamiton. In a randomized trial performed in Vanuatu, in the South Pacific, where scabies is a major public health problem, the cure rate at three weeks was 51 percent (19 of 37 patients) with 10 percent benzyl benzoate, similar to the cure rate of 56 percent with a single oral dose of ivermectin of 200 μg per kilogram of body weight.15 However, a third of the patients treated with benzyl benzoate reported burning or stinging, as compared with 7 percent of those treated with oral ivermectin. In France, where permethrin is not available, benzyl benzoate is considered first-line local treatment, mainly on the basis of professional experience. The Cochrane Review concluded that data were insufficient to compare the effectiveness of either benzyl benzoate or crotamiton with lindane or permethrin.8 However, limited data from a randomized trial suggest that crotamiton has significantly less efficacy than permethrin at four weeks (61 percent vs. 89 percent).16

Pyrethrin has also been used as an aerosol spray (e.g., allethrin) to treat scabies. However, this treatment was associated with severe bronchospasm in two girls with asthma who had head lice and was fatal in one. Such a formulation of pyrethrin should never be prescribed to persons with a history of asthma.17 Sulfur, topical ivermectin, and tea tree oil18 have been suggested as treatments, but data are lacking to support their use.

Oral

Topical treatments may be poorly tolerated by some patients (e.g., they are messy, may be difficult to apply, and may cause burning or stinging, especially when the skin is excoriated or eczematous, and potential percutaneous absorption may pose a risk). An alternative approach is the use of oral ivermectin,19 an agent that has been used extensively for several parasitic infections, including onchocerciasis, lymphatic filariasis, and other nematode-related infestations. Ivermectin is thought to interrupt glutamate-induced and γ-aminobutyric acid–induced neurotransmission in parasites, leading to their paralysis and death.20 In humans, ivermectin does not cross the intact blood–brain barrier, whereas in collies, central nervous system toxicity and associated sudden death have been described.21

Several controlled trials have assessed the efficacy of a single dose of ivermectin (200 μg per kilogram) for the treatment of scabies. In one placebo-controlled trial, 37 of 50 patients treated with ivermectin (74 percent) were cured, as compared with 4 of 26 patients in the placebo group (15 percent).22 In small studies, no significant differences in clinical cure rates were found between ivermectin and 10 percent benzyl benzoate,15 or between ivermectin and lindane.23 In one randomized trial comparing oral ivermectin with an overnight application of 5 percent permethrin,24 a single dose of ivermectin cured 70 percent of patients, as compared with a 98 percent cure rate with permethrin (P<0.003), but a second ivermectin dose taken two weeks later increased the cure rate to 95 percent. The lower efficacy of single-dose ivermectin could reflect the lack of ovicidal action of the drug.

Randomized trials and clinical experience have suggested that ivermectin is safe. Encephalopathy has been reported in patients who are treated with this agent and who have onchocerciasis and are heavily infected with Loa loa microfilariae.25 No serious adverse effects were noted in a program of mass treatment with ivermectin for children with scabies in the Solomon Islands.26 In one study, an excess risk of death was reported among elderly patients who received ivermectin for scabies,27 but selection bias and confounding factors were possible explanations; this observation has not been confirmed in other studies, including studies of residents in nursing homes.28

Ivermectin may be used as first-line therapy, but its higher cost in some countries supports consideration of initial therapy with topical agents. Ivermectin should be routine therapy for patients who have no response to a topical scabicide, and it may be the appropriate first choice for the elderly, patients with generalized eczema, and other patients who may be unable to tolerate or comply with topical therapy.

Assessing the Response

Patients should be advised that itching can persist for up to four weeks after the end of correctly administered scabicide therapy. After that time, the cause of itching should be reinvestigated (Table 3Table 3Main Causes of Itching after Scabicide Therapy.).

Control of Infectivity

Classic scabies is transmitted most commonly by prolonged skin-to-skin contact with the infested person. Persons who have contact of this nature, but not those with more casual contact, should be treated. Prescriptions should be provided for all household members and any sexual contacts, even if they are asymptomatic. The time course for the eradication of parasites after treatment for classic scabies has not been extensively studied, but there is some concern that patients treated with ivermectin may remain contagious longer than those treated with topical therapies.

Crusted scabies is very easily transmissible, and treatment of persons who have been even minimally exposed is warranted. In institutional settings, patient care staff and support staff (e.g., cleaning staff and laundry employees) should be considered to have been exposed to infested persons.

The spread of classic scabies without direct person-to-person contact is rare. However, the recovery of live mites from chairs and couches in the homes of patients with scabies supports the use of environmental measures,29 even though data are lacking to confirm the efficacy of such measures in reducing transmission. Ideally, clothes and bed linens should be machine washed at 60°C and machine dried the day after the first treatment30; insecticide powder or aerosolized insecticide is generally reserved for materials that cannot be laundered. Items may also be kept in a sealed plastic bag for at least 48 to 72 hours. On the basis of the survival of mites, only clothes and linens that were in contact with the patient during the previous 48 to 72 hours warrant these cleaning procedures.

Areas of Uncertainty

A sensitive and specific method for the diagnosis of scabies is lacking. Newer approaches are under investigation, including measurement of specific circulating IgE levels or molecular tools such as polymerase chain reaction followed by enzyme-linked immunosorbent assay or DNA fingerprinting.31 Preliminary studies have suggested that epiluminescence microscopy32 and noncomputed dermoscopy33 — noninvasive techniques allowing detailed inspection of the skin — may be useful. The role of these tests in practice remains uncertain.

Optimal therapy for classic scabies is not certain. Topical treatments may be poorly tolerated. Oral ivermectin is convenient, but the optimal dosing regimen remains uncertain, post-marketing surveillance is mandatory, and the cost is generally higher than that of topical treatments. Limited data suggest that one dose of 200 μg per kilogram may be insufficient.24 Alternative approaches include repeating the dose on day 14 or giving a single dose of 400 μg per kilogram.34 The elimination half-life and the incubation time of 15 days to egg hatching suggest that administration of a second dose of ivermectin on day 14 might be more effective than a single dose, although comparative studies are lacking.

Further study of treatments for crusted scabies is also needed, including the roles of isolation of the index case, combined oral and topical therapy, repeated administration of therapy, and the use of a softening agent both to treat hyperkeratosis and to increase the efficacy of topical scabicides. The potential emergence of ivermectin-resistant scabies mites should be assessed,35 along with the risk of cross-resistance of other parasites, notably in developing countries. Tolerance of mites to permethrin has been demonstrated in vitro, but there has not been in vivo evidence of tolerance or resistance.36

Guidelines

Recommendations for the detection and management of scabies have been issued by several organizations. A fact sheet for patients that is available from the CDC14 recommends examining skin scrapings to confirm the diagnosis and the use of 5 percent permethrin as standard therapy, with crotamiton or oral ivermectin as alternatives; these recommendations also apply to HIV-infected patients with classic scabies. When oral ivermectin is prescribed, the CDC recommends a dose of 200 μg per kilogram, repeated two weeks later.37 National guidelines in the United Kingdom recommend screening for other sexually transmitted infections in patients who present with scabies at clinics for genitourinary medicine.38 Guidelines in the United Kingdom recommend permethrin as the treatment of choice.

Summary and Recommendations

Patients with scabies should be informed that scabies is benign but transmissible and that several treatments are available (Table 2). Treatment should be recommended on the basis of a confirmed diagnosis. Topical permethrin is reasonable first-line therapy in the United States. Where permethrin is not available (e.g., in France), topical benzyl benzoate or oral ivermectin are good choices. Oral ivermectin is preferred for patients who cannot tolerate topical therapy and those who are unlikely to adhere to a regimen of such therapy.

If ivermectin is used to treat the man described in the vignette, limited data and my professional experience would lead me to recommend administration of a dose of 200 μg per kilogram, repeated two weeks later. Close contacts of the man should also be treated, and I would provide a prescription to treat his girlfriend at the same time, even if she were asymptomatic. I would also recommend machine washing and drying recently worn clothes and bed linens. The patient should be followed to confirm resolution of itching, which may take up to four weeks.

Dr. Chosidow reports having received consulting fees from Johnson & Johnson. No other potential conflict of interest relevant to this article was reported.

I am indebted to A. Mahé, A. Petit, R.S. Stern, and S.F. Walton for their helpful comments; to B. Cribier, C. Francès, A. Izri, and J. Revuz for providing some of the figures; and to J. Jacobson for editorial assistance.

Source Information

From Université Pierre et Marie Curie, Paris 6, and the Department of Dermatology and Allergy, Assistance Publique–Hôpitaux de Paris, Hôpital Tenon, Paris.

Address reprint requests to Dr. Chosidow at the Department of Dermatology and Allergy, Hôpital Tenon, 4, rue de la Chine, 75970 Paris CEDEX 20, France, or at olivier.chosidow@tnn.aphp.fr.

References

References

1. 1

   Downs AMR, Harvey I, Kennedy CTC. The epidemiology of head lice and scabies in the UK. Epidemiol Infect 1999;122:471-477
   CrossRef | Web of Science | Medline

2. 2

   Walton SF, Holt DC, Currie BJ, Kemp DJ. Scabies: new future for a neglected disease. Adv Parasitol 2004;57:309-376
   CrossRef | Web of Science | Medline

3. 3

   Arlian LG, Runyan RA, Achar S, Estes SA. Survival and infectivity of Sarcoptes scabiei var. canis and var. hominis. J Am Acad Dermatol 1984;11:210-215
   CrossRef | Web of Science | Medline

4. 4

   Otero L, Varela JA, Espinosa E, et al. Sarcoptes scabiei in a sexually transmitted infections unit: a 15-year study. Sex Transm Dis 2004;31:761-765
   CrossRef | Web of Science | Medline

5. 5

   Mahe A, Faye O, N'Diaye HT, et al. Definition of an algorithm for the management of common skin diseases at primary health care level in sub-Saharan Africa. Trans R Soc Trop Med Hyg 2005;99:39-47
   CrossRef | Web of Science | Medline

6. 6

   Orkin M. Scabies: what's new? Curr Probl Dermatol 1995;22:105-111
   Medline

7. 7

   Falk ES, Eide TJ. Histologic and clinical findings in human scabies. Int J Dermatol 1981;20:600-605
   CrossRef | Web of Science | Medline

8. 8

   Walker GJA, Johnstone PW. Interventions for treating scabies. Cochrane Database Syst Rev 2000;3:CD000320-CD000320
   Medline

9. 9

   Bigby M. A systematic review of the treatment of scabies. Arch Dermatol 2000;136:387-389
   CrossRef | Web of Science | Medline

10. 10

    Schultz MW, Gomez M, Hansen RC, et al. Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch Dermatol 1990;126:167-170
    CrossRef | Web of Science | Medline

11. 11

    Bhalla M, Thami GP. Reversible neurotoxicity after an overdose of topical lindane in an infant. Pediatr Dermatol 2004;21:597-599
    CrossRef | Web of Science | Medline

12. 12

    Franz TJ, Lehman PA, Franz SF, Guin JD. Comparative percutaneous absorption of lindane and permethrin. Arch Dermatol 1996;132:901-905
    CrossRef | Web of Science | Medline

13. 13

    Meinking TL, Taplin D. Safety of permethrin vs lindane for the treatment of scabies. Arch Dermatol 1996;132:959-962
    CrossRef | Web of Science | Medline

14. 14

    Scabies fact sheet. Atlanta: Centers for Disease Control and Prevention, 2005. (Accessed March 24, 2006, at http://www.cdc.gov/ncidod/dpd/parasites/scabies/factsht_scabies.htm.)
    

15. 15

    Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health 2002;38:401-404
    CrossRef | Web of Science | Medline

16. 16

    Taplin D, Meinking TL, Chen JA, Sanchez R. Comparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. Pediatr Dermatol 1990;7:67-73
    CrossRef | Web of Science | Medline

17. 17

    Chosidow O. Scabies and pediculosis. Lancet 2000;355:819-826
    CrossRef | Web of Science | Medline

18. 18

    Walton SF, McKinnon M, Pizzutto S, Dougall A, Williams E, Currie BJ. Acaricidal activity of Melaleuca alternifolia (tea tree) oil: in vitro sensitivity of Sarcoptes scabiei var hominis to terpinen-4-oil. Arch Dermatol 2004;140:563-566
    CrossRef | Web of Science | Medline

19. 19

    Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. N Engl J Med 1995;333:26-30
    Full Text | Web of Science | Medline

20. 20

    del Giudice P, Chosidow O, Caumes E. Ivermectin in dermatology. J Drugs Dermatol 2003;2:13-21
    Medline

21. 21

    Roulet A, Puel O, Gesta S, et al. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 2003;460:85-91
    CrossRef | Web of Science | Medline

22. 22

    Macotela-Ruiz E, Pena-Gonzalez G. Tratamiento de la escabiasis con ivermectina por via oral. Gac Med Mex 1993;129:201-205
    Medline

23. 23

    Chouela EN, Abeldano AM, Pellerano G, et al. Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Dermatol 1999;135:651-655
    CrossRef | Web of Science | Medline

24. 24

    Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000;42:236-240
    CrossRef | Web of Science | Medline

25. 25

    Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997;350:18-22
    CrossRef | Web of Science | Medline

26. 26

    Lawrence G, Leafasia J, Sheridan J, et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Health Organ 2005;83:34-42
    Web of Science | Medline

27. 27

    Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997;349:1144-1145
    CrossRef | Web of Science | Medline

28. 28

    del Giudice P, Marty P, Gari-Toussaint M, Le Fichoux Y. Ivermectin in elderly patients. Arch Dermatol 1999;135:351-352
    CrossRef | Web of Science | Medline

29. 29

    Arlian LG, Estes SA, Vyszenski-Moher DL. Prevalence of Sarcoptes scabiei in the homes and nursing homes of scabietic patients. J Am Acad Dermatol 1988;19:806-811
    CrossRef | Web of Science | Medline

30. 30

    Elston DM. Controversies concerning the treatment of lice and scabies. J Am Acad Dermatol 2002;46:794-796
    CrossRef | Web of Science | Medline

31. 31

    Walton SF, McBroom J, Mathews JD, Kemp DJ, Currie BJ. Crusted scabies: a molecular analysis of Sarcoptes scabiei variety hominis populations from patients with repeated infestations. Clin Infect Dis 1999;29:1226-1230
    CrossRef | Web of Science | Medline

32. 32

    Argenziano G, Fabbrocini G, Delfino M. Epiluminescence microscopy: a new approach to in vivo detection of Sarcoptes scabiei. Arch Dermatol 1997;133:751-753
    CrossRef | Web of Science | Medline

33. 33

    Prins C, Stucki L, French L, Saurat JH, Braun RP. Dermoscopy for the in vivo detection of Sarcoptes scabiei. Dermatology 2004;208:241-243
    CrossRef | Web of Science | Medline

34. 34

    Burkhart CG, Burkhart CN. Optimal treatment for scabies remains undetermined. J Am Acad Dermatol 2001;45:637-638
    CrossRef | Web of Science | Medline

35. 35

    Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis 2004;39:e8-e12
    CrossRef | Web of Science | Medline

36. 36

    Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg 2000;94:92-96
    CrossRef | Web of Science | Medline

37. 37

    Sexually transmitted diseases treatment guidelines — 2002. Atlanta: Centers for Disease Control and Prevention, 2002. (Accessed March 24, 2006, at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5106a1.htm.)
    

38. 38

    National guidelines for the management of scabies. Sex Transm Infect 1999;75:Suppl 1:S76-S77
    Web of Science | Medline

Citing Articles (40)

Citing Articles

1. 1

   Laurence Le Cleach, Olivier Chosidow. (2011) Commentary on ‘Interventions for treating scabies’. Evidence-Based Child Health: A Cochrane Review Journal 6:6, 1865-1866
   CrossRef

2. 2

   F. Bellarbre, B. Fougère, C. Baudemont, I. Merlet-Chicoine, M. Paccalin. (2011) Crusted scabies: Misdiagnosis in the elderly. European Geriatric Medicine 2:4, 251-252
   CrossRef

3. 3

   Anjum Khan, Sharon O’Grady, Matthew Paul Muller. (2011) Rapid control of a scabies outbreak at a tertiary care hospital without ward closure. American Journal of Infection Control
   CrossRef

4. 4

   Khadija Baccouche, Jérémie Sellam, Sarah Guegan, Sélim Aractingi, Francis Berenbaum. (2011) Gale croûteuse norvégienne, une infection opportuniste, survenant sous tocilizumab dans le traitement de la polyarthrite rhumatoïde. Revue du Rhumatisme 78:4, 382-384
   CrossRef

5. 5

   Khadija Baccouche, Jérémie Sellam, Sarah Guegan, Sélim Aractingi, Francis Berenbaum. (2011) Crusted Norwegian scabies, an opportunistic infection, with tocilizumab in rheumatoid arthritis. Joint Bone Spine 78:4, 402-404
   CrossRef

6. 6

   Julie S. Prendiville. 2011. Scabies and Lice. , 72.1-72.16.
   CrossRef

7. 7

   Esther Sacoun. (2011) Gale et poux sont toujours d’actualité. Option/Bio 22:454, 12-13
   CrossRef

8. 8

   Amy J. Behrman. 2011. Health Hazards and Emergency Care for Health Care Workers. , 175-198.
   CrossRef

9. 9

   Heidi Collins Fantasia, Holly B. Fontenot, Melissa Sutherland, Allyssa L. Harris. (2011) Sexually Transmitted Infections in Women. Nursing for Women's Health 15:1, 46-58
   CrossRef

10. 10

    Baik Kee Cho. (2011) Reemerging skin disease caused by arthropods I: scabies. Journal of the Korean Medical Association 54:5, 511
    CrossRef

11. 11

    Ming-Yuan Hong, Ching-Chi Lee, Ming-Che Chuang, Sheau-Chiou Chao, Ming-Che Tsai, Chih-Hsien Chi. (2010) Factors Related to Missed Diagnosis of Incidental Scabies Infestations in Patients Admitted Through the Emergency Department to Inpatient Services. Academic Emergency Medicine 17:9, 958-964
    CrossRef

12. 12

    N. Srifi, J. El Gordo, H. Bourra, M. Lyagoubi, B. Hassam, S. Aoufi, K. Senouci. (2010) Plaques squameuses alopéciques du cuir chevelu. Annales de Dermatologie et de Vénéréologie 137:5, 396-399
    CrossRef

13. 13

    Sophie Bouvresse, Olivier Chosidow. (2010) Scabies in healthcare settings. Current Opinion in Infectious Diseases 23:2, 111-118
    CrossRef

14. 14

    Chosidow, Olivier, Giraudeau, Bruno, Cottrell, Jeremy, Izri, Arezki, Hofmann, Robert, Mann, Stephen G., Burgess, Ian, . (2010) Oral Ivermectin versus Malathion Lotion for Difficult-to-Treat Head Lice. New England Journal of Medicine 362:10, 896-905
    Full Text

15. 15

    Carmen Merkler. (2010) Scabies: Neglected or Forgotten?. Infectious Diseases in Clinical Practice 18:2, 85-86
    CrossRef

16. 16

    Currie, Bart J., McCarthy, James S., . (2010) Permethrin and Ivermectin for Scabies. New England Journal of Medicine 362:8, 717-725
    Full Text

17. 17

    Carlos Nicolas Prieto-Granada, Alice Z.C. Lobo, Martin C. Mihm. 2010. Skin Infections. , 519-616.
    CrossRef

18. 18

    James H. Diaz. (2010) Mite-Transmitted Dermatoses and Infectious Diseases in Returning Travelers. Journal of Travel Medicine 17:1, 21-31
    CrossRef

19. 19

    James J. Nordlund. (2009) Cutaneous ectoparasites. Dermatologic Therapy 22:6, 503-517
    CrossRef

20. 20

    Kuniko MAKIGAMI, Noriko OHTAKI, Norihisa ISHII, Seiji YASUMURA. (2009) Risk factors of scabies in psychiatric and long-term care hospitals: A nationwide mail-in survey in Japan. The Journal of Dermatology 36:9, 491-498
    CrossRef

21. 21

    Sophie Lin, Jeffrey Farber, Luciana Lado. (2009) A Case Report of Crusted Scabies with Methicillin-Resistant Staphylococcus Aureus Bacteremia. Journal of the American Geriatrics Society 57:9, 1713-1714
    CrossRef

22. 22

    Justin James Roesch, Shan-Ze Wang, George D. Comerci, Claudia Quinonez, Shilpa Gopal Reddy, David Rogers. (2009) Bugs and Blood Cells. The American Journal of Medicine 122:7, 632-635
    CrossRef

23. 23

    Kosta Y Mumcuoglu, Leon Gilead, Arieh Ingber. (2009) New insights in pediculosis and scabies. Expert Review of Dermatology 4:3, 285-302
    CrossRef

24. 24

    Hermann Feldmeier, Anne Jackson, Liana Ariza, Cláudia Maria Lins Calheiros, Valquiria de Lima Soares, Fabíola A. Oliveira, Ulrich R. Hengge, Jörg Heukelbach. (2009) The epidemiology of scabies in an impoverished community in rural Brazil: Presence and severity of disease are associated with poor living conditions and illiteracy. Journal of the American Academy of Dermatology 60:3, 436-443
    CrossRef

25. 25

    C. Hafner. (2009) Skabies. Der Hautarzt 60:2, 145-161
    CrossRef

26. 26

    Kevin P. High, Suzanne F. Bradley, Stefan Gravenstein, David R. Mehr, Vincent J. Quagliarello, Chesley Richards, Thomas T. Yoshikawa. (2009) Clinical Practice Guideline for the Evaluation of Fever and Infection in Older Adult Residents of Long‐Term Care Facilities: 2008 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 48:2, 149-171
    CrossRef

27. 27

    Seon Pil Jin, Ji Eun Choi, Chong-Hyun Won, Soyun Cho. (2009) Scabies in a 2-month-old Infant Successfully Treated with Lindane. Annals of Dermatology 21:2, 200
    CrossRef

28. 28

    M. Royer, C.-M. Latre, C. Paul, J. Mazereeuw-Hautier. (2008) La gale du nourrisson. Annales de Dermatologie et de Vénéréologie 135:12, 876-881
    CrossRef

29. 29

    Márta Jenei, Imre Veres, Emese Schmidt, Imre Varga, Éva Remenyik. (2008) Az erythrodermáról és rühatkafertőzésről scabies norvegica két esete kapcsán. Orvosi Hetilap 149:47, 2229-2235
    CrossRef

30. 30

    Patrick Hochedez, Eric Caumes. (2008) Common Skin Infections in Travelers. Journal of Travel Medicine 15:4, 252-262
    CrossRef

31. 31

    , . (2008) Guideline for the diagnosis and treatment of scabies in Japan (second edition). The Journal of Dermatology 35:6, 378-393
    CrossRef

32. 32

    N. N. Goyal, G. A. Wong. (2008) Psoriasis or crusted scabies. Clinical and Experimental Dermatology 33:2, 211-212
    CrossRef

33. 33

    S. Badiaga, C. Foucault, C. Rogier, B. Doudier, C. Rovery, H. T. Dupont, P. Castro, D. Raoult, P. Brouqui. (2008) The effect of a single dose of oral ivermectin on pruritus in the homeless. Journal of Antimicrobial Chemotherapy 62:2, 404-409
    CrossRef

34. 34

    C. Ram-Wolff, E. Mahé, P. Saiag, J. Dunand. (2008) Gale croûteuse localisée sous le niveau lésionnel de l’atteinte médullaire chez un malade paraplégique. Annales de Dermatologie et de Vénéréologie 135:1, 68-69
    CrossRef

35. 35

    Patrick Hochedez, Eric Caumes. (2007) Hookworm-Related Cutaneous Larva Migrans. Journal of Travel Medicine 14:5, 326-333
    CrossRef

36. 36

    Brittany Tesner, Nicole O. Williams, Robert T. Brodell. (2007) The pathophysiologic basis of scabietic nodules. Journal of the American Academy of Dermatology 57:2, S56-S57
    CrossRef

37. 37

    OT Mytton, R McGready, SJ Lee, CH Roberts, EA Ashley, VI Carrara, KL Thwai, MP Jay, T Wiangambun, P Singhasivanon, F Nosten. (2007) Safety of benzyl benzoate lotion and permethrin in pregnancy: a retrospective matched cohort study. BJOG: An International Journal of Obstetrics & Gynaecology 114:5, 582-587
    CrossRef

38. 38

    Anne Jackson, Jörg Heukelbach, Arthur Ferreira da Silva Filho, Evônio de Barros Campelo Júnior, Hermann Feldmeier. (2007) Clinical features and associated morbidity of scabies in a rural community in Alagoas, Brazil. Tropical Medicine & International Health 12:4, 493-502
    CrossRef

39. 39

    L. Dehen, O. Chosidow. (2007) Ectoparasitosis. EMC - Dermatolog??a 41:3, 1-16
    CrossRef

40. 40

    LeAnne M Fox. (2006) Ivermectin: uses and impact 20 years on. Current Opinion in Infectious Diseases 19:6, 588-593
    CrossRef